Setara launches with $90M Series A to advance rare disease assets left over from Jazz's Actio buyout
- Setara Biosciences debuted with a $90M Series A, backed by Deerfield, Regeneron Ventures, Jazz and others.
- It holds the small-molecule programs Jazz did not keep when it bought Actio; Actio founder David Goldstein is CEO.
- Lead candidate STAR-0871, a TRPV4 inhibitor, targets CMT2C and overactive bladder, with Phase 1b and 2a studies planned for 2027.
💡 Points Based on public reports
A $90M round for assets the acquirer chose not to keep says more about Jazz's focus than about the molecules. Jazz stays on the cap table, so it holds a cheap option on STAR-0871 without funding development. The real test is pairing rare CMT2C with large-market overactive bladder: it gives a clear path, but clinical studies don't start until 2027.
New biotech Setara forms with $90M to take on Jazz's bonus rare disease programs ↗